Medications for attention deficit hyperactivity disorder: Cardiovascular concerns

CMAJ. Canadian Medical Association Journal

Volumn 175, Issue 1, 2006, Pages 29-30

  Wooltorton, Eric ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; ATOMOXETINE; ATTENADE; BIPHENTIN; DEXAMPHETAMINE; METHYLPHENIDATE; RITALIN XR; STRATERRA; CENTRAL STIMULANT AGENT;

ATTENTION DEFICIT DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; HEART ARRHYTHMIA; HEART DEATH; HEART INFARCTION; HUMAN; PRESCRIPTION; SHORT SURVEY; STROKE; SUDDEN DEATH; SYNCOPE; THORAX PAIN; ARTICLE; CANADA; CHEMICALLY INDUCED DISORDER; PACKAGING; RISK FACTOR;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CANADA; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM STIMULANTS; DEATH, SUDDEN, CARDIAC; HUMANS; PRODUCT LABELING; RISK FACTORS;

EID: 33745902516     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.060718     Document Type: Short Survey

References (2)

1. Attention deficit hyperactivity disorder (ADHD) drugs: updated and standardized labelling regarding very rare cardiac-related adverse events [dear healthcare professional letter]. Ottawa: Health Canada; 2006. Available: www.hc-sc.gc.ca/dhp-mp /medeff/advisories-avis/prof/2006/adhd-tdah_medic_hpc- cps_e.html (accessed 2006 Jun 8).
2. Office of Drug Safety. Follow up review of AERS search identifying cases of sudden death occuring with drugs used for the treatment of attention deficit hyperactivity disorder (ADHD). Rockville (MD): US Food and Drug Administration; 2006. Available: www.fda.gov/ohrms/dockets/ac/06 /briefing/2006- 4210b_07_01_safetyreview.pdf (accessed 2006 Jun 8).